Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (2) , 408-415
Abstract
Background: Previous studies suggest S100A9 is a promising biomarker for prognosis in cancer, including hepatocellular carcinoma (HCC). We examined the utility of serum S100A9 in predicting prognosis in HCC after curative resection.Keywords
This publication has 31 references indexed in Scilit:
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 2014
- Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based PlatformClinical Cancer Research, 2014
- High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcomeEuropean Journal of Cancer, 2014
- S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapyAnnals of Oncology, 2014
- A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4Oncogene, 2014
- A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancerAnnals of Oncology, 2013
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- S100A8 and S100A9 Are Novel Nuclear Factor Kappa B Target Genes During Malignant Progression of Murine and Human Liver Carcinogenesis†Hepatology, 2009
- RAGE signaling sustains inflammation and promotes tumor developmentJournal of Experimental Medicine, 2008
- S100A8 and S100A9 in inflammation and cancerBiochemical Pharmacology, 2006